LGND: XOMA Buy Adds 100+ Assets [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
In an April 27 th press release , Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) announced that it will acquire XOMA Royalty Corporation (NASDAQ: XOMA) for $39 per share in an all-cash transaction. XOMA shareholders will receive a Contingent Value Right (CVR) entitling the holder to receive a 75% of any net proceeds that may result from pending Tremfya litigation with Janssen. The merger requires cash redemption of XOMA's preferred stock, repayment of loans, along with cash settlements of in-the-money options and certain warrants. The total value of the purchase is estimated to be $739 million. It will be funded through cash on Ligand's balance sheet and borrowings under an existing credit facility. Management issued a press release Form 8-K, and slide deck accompanied by a conference call on the morning of April 27 th , 2026, to provide the relevant details. The transaction is expected to close in the third quarter of 2026 and to be immediately accretive to Ligand's earnings. 2026 re
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) had its price target raised by Royal Bank Of Canada from $235.00 to $252.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook [Yahoo! Finance]Yahoo! Finance
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationPR Newswire
- Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]Seeking Alpha
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 4/28/26 - Form DEFA14A
- 4/27/26 - Form DEFA14A
- 4/27/26 - Form 8-K
- LGND's page on the SEC website